Peak Minerals Limited

PUA

Peak Minerals Ltd. engages in the exploration and evaluation of gold, copper, and nickel deposits in Australia. The firm has a diversified multi-commodity portfolio of under-explored Australian copper and nickel assets. Its Western Australian Copper Projects consist of the three assets: Green Rocks Project, Earaheedy Project and Kimberley Projects. The Green Rocks Project is located approximately 35 kilometers (km) to the southeast of Meekatharra and covers 234 square kilometers (km2). The tenure is a combination of 100% held ground and two joint ventures with Taruga Minerals (E51/1832) and Technology Metals Australia (E51/1818). The Earaheedy Project is located 28km southeast of Degrussa Copper-gold Mine. The firm has seven projects in the East Kimberley, and they can be divided into magmatic sulfide or sedimentary copper related mineralization. The firm also completed the analysis of a number of unsampled holes at its Yendon Kaolin Project, which is located 18 km southeast of Ballarat in Victoria.

Prescient Therapeutics Limited

PTX

Prescient Therapeutics Ltd. is a biopharmaceutical company, which engages in the discovery and development of novel immunotherapeutic products for the treatment of chronic infectious diseases and cancer. The company is headquartered in South Melbourne, Victoria. The firm is developing personalized medicine approaches to cancer, including targeted and cellular therapies. Its product pipeline includes PTX-100, PTX-200, OmniCAR, CellPryme-M and CellPryme-A. PTX-100 has completed Phase Ib expansion cohort study in relapsed and refractory T cell lymphomas. PTX-200 is a PH domain inhibitor that inhibits a tumor survival pathway, Akt. OmniCAR is a universal immune receptor platform being developed to enable controllable T-cell activity and multi-antigen targeting with a single-cell product. CellPryme-M technology enhances adoptive cell therapy performance by shifting T and NK cells towards a central memory phenotype, improving persistence, and increasing the ability to find and penetrate tumors. CellPryme-A is an adjuvant therapy designed to be administered to patients alongside cellular immunotherapy to help them overcome a suppressive tumor microenvironment.